Back to catalogue
№ 086 20 filings · 2021-09-15 → 2026-10-07

BRIDGEPOINT GROUP PLC

BPT
Financial Services Share price 402p Market cap £3.6bn Overall fit 680 /1000

Strong operating leverage demonstrably coming through, legitimate (if indirect) AI-receiver exposure via ECP's power infrastructure, fair-to-cheap valuation vs peers, and acceptable balance-sheet quality — missing only direct AI-receiver status to score higher.

Fair value range 400p–520p Mid case · £5.1bn
Absolute upside +38.8% vs current market cap
Conviction 4/5 confidence in undervalued call
Supports the call
  • Multiple valuation approaches converge in similar range
  • Fund-level and PRE disclosure is granular
  • Consistent beats and upward guidance revisions over 2024-2026
Limits the call
  • ProEnergy mark carries acknowledged execution/timing uncertainty
  • KARE earn-out and share-issuance mechanics create per-share variability
Methodology

Blended forward P/E and EV/EBITDA on 2027 pro-forma earnings

In one line · bull case

Scaled middle-market alt manager with real AI-adjacent exposure via ECP, locked-in operating leverage into FY27, and a rebased cash-return framework trading at ~12x forward earnings versus a mid-teens peer multiple.

In one line · biggest risk

A delayed or lower-than-marked ProEnergy realisation would deflate the 2026/27 PRE trajectory that underpins the recent guidance upgrade.

Drivers
AI beneficiary 50 /100
Indirect via ECP's US gas-generation and data-centre power infrastructure (ProEnergy order book, KKR data-centre JV) rather than direct AI tooling.
Operating leverage 80 /100
Classic asset-manager model: H1 2026 showed 22.8% fee growth translating to 77.6% EBITDA growth; margin now guided to ~60%.
Earnings vs expectations 75 /100
Three consecutive reporting cycles with upward guidance revisions; October 2026 upgrade to 2026 and medium-term PRE and EBITDA.
Growth momentum 80 /100
AUM up 32.7% YoY (fee-paying), management fees +22.8% H1 2026, underlying EBITDA +77.6%, €28bn fundraising target hit a quarter early.
Moat 65 /100
Durable LP relationships, strong fund performance track record (BDC III 5.0x, ECP V 3.1x), scaled distribution; competitive industry limits width.
Earnings quality 60 /100
Significant adjustments between reported and underlying (exceptionals, PRE adjustments, CLO consolidations) but cash conversion solid and disclosure thorough.
Management quality 72 /100
Executed ECP integration, Newbury addition and KARE acquisition on strategy; disciplined capital allocation with new distribution framework.
Cyclicality 55 /100
Private-markets fundraising and realisation cycles create moderate cyclicality; closed-end structure provides locked-up fee base.
Leverage 40 /100
Net leverage 0.7x LTM EBITDA at H1 2026, expected to peak at ~2x post-KARE and reduce to <1x within 18 months.

Bridgepoint Group PLC (BPT) — Research Note

Executive summary

Bridgepoint is a scaled European-headquartered middle-market alternative asset manager with a diversified platform spanning private equity (€36bn AUM), infrastructure via Energy Capital Partners (€28bn), credit (€18bn), secondaries (Newbury, €3bn), and — from January 2027 — US real estate via Kayne Anderson Real Estate (adding ~$22bn). The operating trajectory has been exceptional: Fee Paying AUM grew 32.7% YoY in H1 2026 to $58.4bn, H1 2026 underlying EBITDA rose 77.6% to £227.3m, and on 7 October 2026 management materially upgraded 2026 guidance and raised medium-term PRE guidance to 25-30% of total income (from 20-25%), driven in large part by the ProEnergy gas-turbine business inside ECP V marking at >4x 2026-10-07 trading update. The single most important valuation issue is that current market cap (£2,990m) sits well below the earnings power implied by the upgraded 2027 EBITDA margin of ~60%, the £2.4bn five-year cash-from-profits guidance, and the KARE accretion (mid-single-digit EPS in 2027, >20% in 2028).

Fair value estimate

Range: 400p – 520p per share, implied equity value £4.4bn – £5.7bn (using pro-forma post-KARE diluted share count of c.1,100m).

  • Methodology: blended forward P/E and EV/EBITDA on 2027 pro-forma metrics.
  • Key assumptions: 2027 underlying EBITDA £550-650m (upgraded guidance of ~60% margin applied to pro-forma total income, plus KARE contribution); underlying profit after tax ~£350-420m; forward P/E of 12-14x (discount to US-listed peers like Blackstone/KKR but in line with Partners Group/ICG given lower growth optionality from European mix); EV/EBITDA 10-12x; net debt peaking at ~2x then reducing.
  • Comparison to current market cap £2,990m: midpoint fair value ~460p implies ~25% upside vs. current 367.80p; downside case fair value floor around current price.
  • Conviction note: the fair-value calculation is heavily sensitive to the carry realisation profile from ProEnergy and the Calpine lock-up share conversions; both are specifically risk-weighted in the valuation.

Sector context

ICB sector is Financial Services; Bridgepoint is best classified as an alternative asset manager / private markets. Quality and growth profile is above typical UK financials peers: durable fee base, long-duration locked-up capital, 60% EBITDA margin target, and a clear growth path toward $200bn AUM by 2029/30. Comparable listed peers: Intermediate Capital Group (ICG), Partners Group, EQT AB, and Petershill Partners.

Investment thesis (3 bullets)

  • AI-adjacent infrastructure exposure via ECP is accretive and under-priced. ECP's portfolio owns scaled US gas-generation and energy-transition assets — ProEnergy's gas-turbine order book is growing precisely because of hyperscaler data-centre power demand, and ECP announced a Bosque County, Texas 190 MW data-centre campus partnership with KKR. ECP V is now marked at >4x fund-level MOIC and generated the Calpine $33bn exit 2025-03-12 final results; 2026-10-07 trading update. This gives Bridgepoint real revenue participation in the AI power buildout rather than a press-release AI angle.
  • Operating leverage has already started to materialise and will compound. H1 2026 showed 22.8% management-fee growth translating into 77.6% underlying EBITDA growth and a 1,220bps EBITDA margin expansion to 60.6%; medium-term EBITDA margin guidance now 60% 2026-07-17 half-year. With BE VIII (€8.65bn hard cap) now fee-paying and ECP VI closed at $8.1bn (84% larger than ECP V), the next fund cycle locks in a materially higher fee base before incremental cost growth.
  • Valuation does not reflect the step-up in cash returns. The new distribution framework (10p → 15p base dividend plus total returns of 40-60% of Cash from Profits from 2027) is backed by £2.4bn of expected cash receipts over the next five years versus £500m over the past five 2026-10-07 trading update. The current price offers ~4% dividend yield at the rebased 15p, with substantial top-up potential via buybacks/specials.

Key risks (3 bullets)

  • PRE concentration in ProEnergy and Calpine shares. The Q3 2026 valuation uplift on ProEnergy carries a "substantial discount for execution risk and uncertainty in timing of realisation"; a delay or down-mark would compress 2026/27 PRE directly 2026-10-07 trading update. Residual Calpine/Constellation Energy shares (15% of 2026 tranche plus 50% 2027 tranche) remain exposed to CEG share price volatility.
  • Fundraising cycle risk at next vintage. The business is only one disappointing BE VIII final close or a slow BDL IV deployment away from medium-term AUM growth stalling; private markets fundraising remains congested industry-wide, with the 2024 Annual Report flagging extended fundraising timetables as a key risk 2025-03-12 final results.
  • M&A integration and dilution risk. KARE is being paid for with substantial equity issuance (~189m shares plus up to 102.5m earn-out shares); if KARE's $100-150m Earn-Out Revenue thresholds slip, upfront dilution occurs without the full earnings uplift. ECP integration costs continue to burden reported profit (£67m exceptional personnel costs in H1 2026 alone) 2026-07-17 half-year.

Operating leverage

Bridgepoint has textbook asset-manager operating leverage: management fees scale with AUM but the cost base — people (£108.4m H1 2026 underlying personnel), platform (£38.0m other operating expenses), and office leases — is substantially fixed and grows at mid-to-high single digits per management guidance. H1 2026 demonstrated the mechanic clearly: 22.8% fee growth produced 77.6% underlying EBITDA growth, lifting the margin from 48.4% to 60.6%. The 2027 EBITDA margin guidance of ~60% is now locked in by the completion of the €28bn fundraising cycle, with each incremental PRE pound dropping almost directly to EBITDA (modest investment-linked bonus accrual at ~6% of PRE). Where revenue surprises 10-20% above current expectations in 2027/28 — most likely via higher ProEnergy valuation or earlier BE VII carry realisation — operating profit would plausibly rise 20-40%, since the catch-up fee mechanics and PRE economics bypass most variable cost scaling 2026-07-17 half-year; 2026-10-07 trading update.

Value-trap signals

None identified. The accounting is complex (lots of exceptional/adjusted items relating to ECP and KARE) but disclosure is thorough, and the underlying trajectory is accelerating rather than deteriorating.

Earnings vs expectations

Recent pattern: consistent beats and upward guidance revisions. H1 2025 came in ahead of expectations (guidance raised); FY 2025 was "ahead of expectations" with fundraising target raised from €20bn to €24bn; June 2026 saw the fundraising target raised again to €28bn alongside the KARE deal; H1 2026 was described as "ahead of expectations"; October 2026 brought a further material upgrade to 2026 EBITDA and medium-term PRE guidance driven by the ProEnergy mark-up. Across three successive reporting cycles, delivered PRE and management fees have exceeded prior guidance, reinforcing confidence in management's ability to call near-term outcomes.

Conviction

4 — high. The filings disclose fund-level performance, discount rates applied to carried-interest receivables, PRE sensitivity, and granular hedge/liability analysis. Three independent anchors (updated 2027 EBITDA guidance, visible £2.4bn cash-from-profits trajectory to 2030, and traded peer multiples) all converge on a mid-400s pence fair value. Factors limiting conviction: (1) ProEnergy carrying a "substantial discount for execution risk" means the ultimate mark could move materially in either direction; (2) KARE earn-out and share-issuance mechanics make per-share outcomes somewhat path-dependent.

Filings consulted · 28

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-10-07Trading Update2026-10-07_9809935_trading-update.md0.85
  2. 2026-07-28Results OF Secondary Placing2026-07-28_9689919_results-of-secondary-placing.md0.70
  3. 2026-07-27Proposed Secondary Placing OF Ordinary Shares2026-07-27_9689677_proposed-secondary-placing-of-ordinary-shares.md0.70
  4. 2026-07-17Half Year Report2026-07-17_9673554_half-year-report.md0.90
  5. 2026-06-29Acquisition OF Kane Anderson Real Estate2026-06-29_9640400_acquisition-of-kane-anderson-real-estate.md0.75
  6. 2026-05-12Result OF Agm2026-05-12_9564802_result-of-agm.md0.30
  7. 2026-03-26Annual Report And Accounts And Notice OF Agm2026-03-26_9493719_annual-report-and-accounts-and-notice-of-agm.md0.81
  8. 2026-03-12Final Results2026-03-12_9470358_final-results.md0.85
  9. 2025-11-14Results OF Secondary Placing2025-11-14_9232977_results-of-secondary-placing.md0.59
  10. 2025-11-13Proposed Secondary Placing OF Ordinary Shares2025-11-13_9232477_proposed-secondary-placing-of-ordinary-shares.md0.59
  11. 2025-07-18Half Year Report2025-07-18_8985763_half-year-report.md0.58
  12. 2025-05-15Result OF Agm2025-05-15_8880913_result-of-agm.md0.20
  13. 2025-03-26Annual Report And Accounts And Notice OF Agm2025-03-26_8797077_annual-report-and-accounts-and-notice-of-agm.md0.62
  14. 2025-03-13Final Results2025-03-13_8776789_final-results.md0.65
  15. 2024-10-24Capital Markets Day2024-10-24_8505232_capital-markets-day.md0.62
  16. 2024-07-19Half Year Report2024-07-19_8320853_half-year-report.md0.41
  17. 2024-07-15Update ON Financing Acquisition OF Alpha Fmc2024-07-15_8310066_update-on-financing-acquisition-of-alpha-fmc.md0.34
  18. 2024-05-15Result OF Agm2024-05-15_8199534_result-of-agm.md0.14
  19. 2024-04-18Notice OF Agm2024-04-18_8144869_notice-of-agm.md0.14
  20. 2024-03-212023 Annual Report And Accounts2024-03-21_8100172_2023-annual-report-and-accounts.md0.43
  21. 2024-03-14Final Results2024-03-14_8086854_final-results.md0.45
  22. 2023-05-18Result OF Agm2023-05-18_7533279_result-of-agm.md0.07
  23. 2023-03-24Annual Report And Accounts And Notice OF Agm2023-03-24_7280313_annual-report-and-accounts-and-notice-of-agm.md0.24
  24. 2022-11-16Trading Statement2022-11-16_7374222_trading-statement.md0.21
  25. 2022-05-13Result OF Agm2022-05-13_6888603_result-of-agm.md0.07
  26. 2022-03-30Annual Report And Accounts And Notice OF Agm2022-03-30_7093914_annual-report-and-accounts-and-notice-of-agm.md0.24
  27. 2021-11-16Quarterly Trading Update2021-11-16_6739485_quarterly-trading-update.md0.21
  28. 2021-09-15Half Year Update 20212021-09-15_6827261_half-year-update-2021.md0.09

This research note was authored by a large language model after reading 20 regulatory filings published between 2021-09-15 and 2026-10-07. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.